Synthetic heparin could improve blood-thinning treatments
| Autor: | Stu Borman |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Drug
biology Computer Networks and Communications business.industry medicine.drug_class medicine.medical_treatment media_common.quotation_subject Anticoagulant Heparin Pharmacology Fondaparinux Protamine Hardware and Architecture Homogeneous biology.protein medicine business Software Dialysis medicine.drug Uncontrolled bleeding media_common |
| Zdroj: | C&EN Global Enterprise. 95:8-9 |
| ISSN: | 2474-7408 |
| Popis: | A new synthetic version of the sulfated polysaccharide heparin that could be safer or have more-reversible activity than currently approved versions of the anticoagulant has been produced in quantities that begin to approach those needed for commercialization. Three types of heparins are currently approved as blood thinners to treat clotting disorders and prevent clotting in people undergoing kidney dialysis and surgery. Unfractionated heparin and low-molecular-weight heparin, derived from pig intestines, are mixtures with batch-to-batch inconsistencies, and contaminated batches have at times killed people. A synthetic heparin called fondaparinux is safer and homogeneous. But people taking heparin sometimes experience uncontrolled bleeding, and although a drug called protamine can reverse the anticoagulant activity of unfractionated heparin, it does so incompletely with low-molecular-weight heparin and doesn’t reverse fondaparinux activity at all. Robert J. Linhardt of Rensselaer Polytechnic Institute, Ji... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|